In this study we investigated the neuroprotective efficacy of dexmedetomidine (Dex) and phosphocreatine (PCr) alone or in combination in a rat model of focal cerebral ischemia-reperfusion injury (I/R). I/R was induced by intraluminal middle cerebral artery occlusion (MCAO) and reperfusion. Male Sprague-Dawley rats were randomly allocated to the Sham group and I/R group, and the I/R group was further divided into three subgroups: Dex (9 \( \mu g.kg^{-1} \) Dex), PCr (180 mg.kg\(^{-1} \) PCr) and Dex + PCr (9 \( \mu g.kg^{-1} \) Dex + 180 mg.kg\(^{-1} \) PCr). All treatments were given intravenously at the onset of reperfusion. After 24 hr of reperfusion, the neurological deficit score (NDS) was determined and a magnetic resonance imaging (MRI) scan was performed. Serum concentrations of malonaldehyde (MDA) and 4-hydroxynonenal (4-HNE) were measured and cerebral infarct volume was estimated by triphenyl tetrazolium chloride (TTC) staining. Blood brain barrier, neuronal and mitochondrial damage was assessed by optical and electron microscopy. Neuronal injury was further assessed using double cleaved caspase-3 and NeuN immunofluorescent staining. Compared with group I/R, Dex and PCr significantly reduced the neurological deficit score (P < 0.01), infarct volume (P < 0.01), and brain blood barrier, neuronal and mitochondrial damage. The level of oxidative stress (P < 0.001) and neuronal injury (P < 0.001) also decreased and surviving neurons increased (P < 0.001). Compared with Dex or PCr alone, the combination treatment had overall greater effects (P < 0.05). These results indicate that posttreatment with Dex or PCr decreases focal cerebral I/R injury and that these agents in combination have greater protective effects than each alone.

**Key words:** reperfusion injury, post-ischemia treatment, neuroprotection, dexmedetomidine, phosphocreatine

### I. Introduction

The incidence of perioperative stroke is 0.08–0.7% in general surgery and 8–10% in cardiovascular surgery, and perioperative stroke has major negative effects on quality of life and on economic costs in patients who may otherwise have undergone a successful operation [6, 24, 32]. The occurrence and progression of perioperative stroke are unpredictable, which makes post-treatment particularly relevant clinically because intervention may be required after onset of brain ischemia [35].

Various biochemical pathways contribute to development of cerebral I/R injury, with energy depletion and the resultant apoptosis constituting the major pathways that lead to neurological disability during the reperfusion phase [2, 8, 28, 33]. Thus, a combination of pharmacological agents, rather than a single agent, may be more protective...
against cerebral I/R injury [10, 22, 34]. Since pretreatment with dexmedetomidine (Dex) or phosphocreatine (PCr) alone has been found to be neuroprotective [1, 5, 7, 17, 39], the purpose of the present study was to examine the neuroprotective efficacy of Dex and PCr alone or in combination in a rat model of focal cerebral I/R injury.

II. Methods

Animals

Sprague-Dawley rats (grade SPF, weight 220–260 g) were obtained from Anhui Experimental Animal Center (Hefei, China). Before surgery, rats were kept under a 12-hr light/dark cycle and fasted for 12 hr. All experimental procedures in animal surgery were performed in accordance with the Guidelines of the Animal Care and Use Committee of Anhui Medical University. This study was approved by the Ethical Committee of Anhui Medical University (No. LLSC201508216).

MCAO model

A focal cerebral I/R model was established by occlusion of the middle cerebral artery (MCA) for 90 min, followed by reperfusion for 24 hr, as previously described with some changes [13, 16, 20]. After anesthesia with 10% chloral hydrate (350 mg.kg⁻¹ i.p.), a nylon suture (0.24 mm diameter) with a rounded tip was introduced through the right common carotid artery (CCA) into the internal carotid artery (ICA) to occlude the origin of the MCA (about 18 mm from the bifurcation). The filament was withdrawn at 90 min after occlusion to allow reperfusion. In the sham operation, only the right common carotid artery was ligated. Body temperature was monitored and maintained at 37°C with a thermal insulation blanket during surgery.

Drug administration and grouping

Rats were randomly allocated to the Sham, I/R, Dex, PCr, and Dex + PCr groups (total 80, n = 16 per group). Intravenous infusion of the drug was started immediately at onset of reperfusion. Dex and PCr were administered at doses of 3 μg.kg⁻¹ and 180 mg.kg⁻¹, respectively, in 15 min. Each dose was dissolved in 2 ml of normal saline and administered intravenously through the right femoral vein at a constant rate of 8 ml.h⁻¹ immediately after onset of reperfusion. Animals in the Sham and I/R groups were intravenously injected with 2 ml of normal saline through the right femoral vein at the same rate over the same time.

Neurobehavioral evaluation and infarct assessment

Ten rats in each group were examined 24 hr after onset of reperfusion. The NDS was evaluated using the method of Longa et al. by an investigator blinded to the experimental groups [13, 16]. Briefly, the rats were lifted 20–30 cm and their movement was observed and graded as follows: 0 (no symptoms of nerve injury); 1 (contralateral front paws not fully extended); 2 (turning to the opposite side); 3 (pawing to the opposite side); 4 (inability to walk spontaneously and loss of consciousness); and 5 (death). MRI was performed to confirm the ischemic penumbra [38]. The rats were then decapitated and brains were removed for triphenyl tetrazolium chloride (TTC) staining. Infarct volume was calculated using Swanson’s method: (contralateral hemisphere volume ipsilateral hemisphere volume)/contralateral hemisphere volume × 100%.

Cerebral injury

After confirming the ischemic penumbra using MRI, six terminally anesthetized rats in each group were intracardially perfused with phosphate-buffered saline (PBS) followed by 4% paraformaldehyde or 4% glutaraldehyde. Coronal slices of 5 mm were harvested from the chiasma opticum and caudally, and 3-μm coronal slices and the ischemic penumbra were further processed for light and electron microscopy. Pathological changes of hemispheres (×40 and ×400) and damage to the hippocampal ischemic penumbra (×8000 and ×20000) were observed.

Oxidative stress status

Blood samples from 10 rats were placed in a clean dry centrifuge tube, left to clot at 4°C, and then centrifuged for 10 min at 4000 rpm to separate serum. After careful separation, the serum was kept frozen at −20°C until performance of assays for malonaldehyde (MDA) using a Coomassie brilliant blue protein assay kit (Nanjing Jiancheng Bio Co., China) and for 4-hydroxynonenal (4-HNE) using a rat 4HNE ELISA kit (R & D Company, USA).

Neuronal apoptosis

Expression of NeuN and cleaved caspase-3 was detected by immunohistochemical staining, based on reported methods with some changes [9, 25]. Brain sections were incubated with primary antibodies for NeuN (1:400, Cell Signaling) and cleaved caspase-3 (1:400, Cell Signaling) for 2 hr after blocking with 5% goat serum (Vector Labs, Burlingame, CA), and then incubated with secondary antibodies (DAKO, Glostrup, Denmark) at 37°C for 1 hr. After treatment with 3,3’-diaminobenzidine (DAB), staining with hematoxylin, dehydration in ethanol, and mounting in neutral gum in this order, the slides were observed under an optical microscope (Olympus, Tokyo, Japan). The cytoplasm of cells positive for NeuN and cleaved caspase-3 was tan in color. Five non-overlapping fields in the marginal area of the infarct were taken from each slice under high magnification (×400) and the positive cells were counted.

Propidium iodide (PI) staining was used to identify dead cells [18]. Sections were placed in artificial cerebrospinal fluid (ACSF) containing 50 μg/ml PI for 5 min, and then rinsed 3 times in ACSF, followed by PBS. After antigen retrieval, the sections were permeabilized and blocked in PBS containing 0.5% Triton X-100 and 5% goat serum, and then incubated with NeuN (1:50, Cell signaling)
overnight at 4°C. The sections were then incubated with Alexa Fluor 488-conjugated IgG (Invitrogen, Carlsbad, CA, USA) and observed under fluorescent microscopy (Olympus, Tokyo, Japan). Nuclei were stained with 4,6-diamidino-2-phenylindole (DAPI) (5 mg/mL). Image J software was used to analyze PI-positive fluorescence intensity, which was converted into the cortical cell apoptosis rate.

Dual fluorescent staining of NeuN and cleaved caspase-3 was performed to confirm activation of caspase-3 in neurons, using the immunofluorescence procedures described above. Nuclei were stained with DAPI. Five random non-overlapping fields at the edge of the infarct area were selected under high magnification (×400) to count the positive rate of caspase-3 in NeuN-labeled neurons to establish the apoptosis index of the neurons.

**Statistical analysis**

Data analyses were performed with GraphPad Prism (ver. 6, GraphPad Software Inc., San Diego, CA, USA). Comparisons between two groups were evaluated by Student t test, and those among multiple groups were performed by one-way analysis of variance (ANOVA), followed by a Tukey test. P < 0.05 was considered to be statistically significant.

**III. Results**

**Neuroprotection by Dex and PCr after MCAO**

There was significant alleviation of reduced motor function in the treated groups compared to group I/R (Fig. 1A). The ischemic penumbra was confirmed using MRI, with T2-weighted images used to examine the size. On these images (Fig. 1B), the infarct area appears as white and normal brain tissue as gray. Images from the Dex, PCr and Dex + PCr groups all had smaller white areas than that in the I/R group. The infarct volume was also significantly smaller in the Dex, PCr and Dex + PCr groups compared to that in the I/R group (20.13%, 18.31%, 14.94% vs. 24.55%), and an additive neuroprotective effect was seen in the Dex + PCr group compared with the Dex and PCr groups (Fig. 1C, D).
Under optical microscopy at \( \times 100 \) magnification, neurons of the cortex and hippocampus were arranged in neat rows in the Sham group, whereas the structure was sparse because of loss of many cells in the I/R group, especially in the cortex and CA2-CA3 region of the hippocampus. At \( \times 400 \), surviving cells were shrunken or edematous in the I/R group. In the treated groups, more cells had survived with complete membrane integrity and clear nuclei (Fig. 2A).

In electron microscopy, microstructures of the ischemic penumbra could be seen. At \( \times 8000 \) magnification, the membrane structure of the brain blood barrier was incomplete and cerebral tissue was clearly edematous in the I/R group. Apoptotic neurons characterized by shrunken nuclei and aggregated chromatin toward the nuclear membrane were observed. Treatment with Dex and PCr reduced the damage to endothelial cells, decreased exudation and edema, and improved the microcirculation (Fig. 2B).

At \( \times 20000 \), clearly swollen mitochondria and disordered, cracked or decreased cristae were observed. Dex and PCr treatment alone clearly alleviated these effects, and neuronal damage was further improved by use of the two agents in combination (Fig. 2B).
Reduction of oxidative stress post-ischemia by Dex and PCr

Serum MDA and 4-HNE were measured as markers of oxidative stress. I/R significantly increased the levels of these products of oxidative stress at 24 hr after reperfusion. MDA (Fig. 3A) and 4-HNE (Fig. 3B) levels were significantly decreased in the treated groups compared to those in the I/R group.

Inhibition of apoptosis by Dex and PCr

Activation of caspase-3 has previously been shown to be involved in ischemia-induced apoptosis in a rat MCAO model. In this study, we found that Dex and PCr greatly reduced the level of cleaved caspase-3 after MCAO (Fig. 4).

Protection against loss of neurons by Dex and PCr

Apoptotic neurons were labeled using dual immunofluorescence of a neuron marker, NeuN, and an apoptosis marker, caspase-3. In the Sham group, the cerebral cortex was intact and most cells in the cortex were NeuN-positive,
Fig. 5. Inhibition by Dex and PCr of apoptosis induced by I/R. Neurons were detected using immunohistochemistry with an anti-NeuN antibody (green). DAPI (blue) was used to stain nuclei. Double-labeled immunofluorescent staining of NeuN/caspase-3 (A) and DAPI/PI (red) (B) were used to detect dead cells (C) and apoptotic neurons (D), and the dead cell % and apoptotic index were calculated. Data are shown as mean (SD), n = 5. *P < 0.05, **P < 0.01 vs. group I/R; *P < 0.05, **P < 0.01 vs. group Dex + PCr. Bar = 50 μm.
with single-digit caspase-3-positive cells. I/R caused clear neuronal death, as reflected by a decrease in NeuN and an increase in caspase-3 (Fig. 5A). PI fluorescent staining showed that I/R decreased the total cell count and increased the % dead cells. Loss of cells and the % dead cells were both reduced by Dex and PCr (Fig. 5B, C, D).

IV. Discussion

This study is the first to show the combined effects of Dex and PCr on focal cerebral I/R injury in rats. This combination treatment gave improved neuroprotection compared to Dex or PCr alone. Over the last decade, the incidence of perioperative stroke had continued to increase, despite advances in surgical techniques and perioperative care. This trend reflects more surgeries in an aging population with coexisting conditions. Anesthetics are promising agents for perioperative neuroprotection, since barbiturates, propofol and most volatile anesthetics protect cerebral tissue from adverse events such as apoptosis, inflammation and energy failure caused by underlying diseases [15, 23, 27, 29]. Dex has also been reported to be neuroprotective, but an appropriate dose and combination treatment are needed to reduce side effects and improve patient tolerability. Based on the similarity of human and rat cerebral vessels, we established MCAO rats to imitate cerebral I/R in humans, and investigated the potential effects of Dex alone or in combination with phosphocreatine.

Some previous studies in cerebral I/R models have indicated that Dex partially reduces ischemic damage through reduction of glutamate and free radicals [31, 37]. In contrast, other studies have found that high-dose Dex fails to protect against severe ischemia in rats due to resultant hypertension and a high blood glucose concentration [14, 19, 36]. In our preliminary experiments, doses ranging from 3 to 15 μg.kg⁻¹ were used, and we ultimately chose the safest dose of 9 μg.kg⁻¹. This dose caused minor increases in blood glucose and hypotension without any serious systemic adverse side effects, in accordance with a previous study [11]. At this dose of Dex, we found significant decreases in infarct volume (24.55 ± 2.05% vs. 20.13 ± 1.51%), ischemic damage and neuronal death.

To maximize efficacy whilst ensuring safety, PCr was tested in combination with Dex. ATP concentrations in the penumbra are depressed by about 80% after a 90-minute occlusion of the MCA, and then restored to only 37–50% during recirculation [26]. Energy depletion persists throughout the entire I/R period and determines the ultimate extent of injury; therefore, supply of an exogenous energy source may be an important and logical therapeutic step. PCr preconditioning may be effective for ischemic tolerance [21], and in the present study we first confirmed neuroprotection by PCr. Thus, PCr reduced the infarct volume by 25.4% (24.55 ± 2.05% vs. 18.31 ± 2.02%), and improved neurological behavior, histopathological damage and neuronal death. PCr can prevent mitochondrial dysfunction by inhibiting the mitochondrial permeability transition [1], and electron scanning microscopy provided evidence of swollen mitochondria with cracked and disordered cristae in apoptotic neurons induced by I/R. PCr attenuated this mitochondrial damage, with only mild changes seen in the brain blood barrier, neurons and organelles.

The above results show that treatment with Dex or PCr improved morphology and resulted in survival of more neurons and larger organelles with complete membrane structures. The greatest efficacy was found for combination treatment with Dex and PCr, which reduced the infarct volume by 40% (24.55 ± 2.05% vs. 14.94 ± 2.97%). Furthermore, the two agents in combination had better effects on motor performance and neuronal death.

Rapid exhaustion of energy is the initial change in I/R, and energy deficiency then leads to mitochondrial dysfunction, an increase in oxygen free radicals, and ultimately neuronal death. Since mitochondrial dysfunction and lipid peroxidation are important aggravating factors in neuronal death [12], we examined the role of lipid peroxidation and apoptosis in I/R, and the effects of Dex and PCr on oxidative stress and apoptosis. MDA and 4-HNE, which are products of lipid peroxidation, are increased in an experimental stroke rat model and in patients with ischemic stroke [2, 28]. Our results indicate that Dex and PCr are decreased in I/R, in agreement with previous findings [4]. Caspase-3, a key executioner caspase, is constitutively expressed as an inactive precursor in murine brain cells, and chiefly in neurons. During I/R, caspase-3 is cleaved and activated, leading to cell death [3, 30]. In the current study, we found upregulation of cleaved caspase-3 in post-ischemic neurons, and treatment with Dex and PCr reduced expression of cleaved caspase-3. Taken together, these findings may partially explain the neuroprotective effects of Dex and PCr after cerebral ischemia.

There are several limitations in the study, including the lack of variation of the dose of phosphocreatine and of the time for reperfusion prior to the intervention. Thus, further studies are needed to determine the dose-response relationship and the therapeutic window for treatment of cerebral I/R by Dex and PCr. Within these limitations, our results show that post-treatment with Dex and PCr leads to better neurological function, smaller infarct volume, mild histopathologic changes, and less neuronal death in MCAO, compared to use of Dex or PCr alone. Patients with undiagnosed stroke, severe brain injury, hemorrhagic shock and cardiac arrest may benefit from protection using Dex and PCr in the perioperative period.

V. Funding

This study was supported in part by an Anhui Science and Technology Plan Project (No. 1804h08020250).
VI. Conflicts of Interest

The authors declare no conflicts of interest.

VII. Acknowledgments

We are very grateful to W.H. (Department of Pathology, First Affiliated Hospital of the University of Science and Technology of China, Hefei, China) for help with MRI, without which this work could not have been possible.

VIII. References

1. Balestrino, M., Lensman, M., Parodi, M., Perasso, L., Rebaudo, R., Melani, R., et al. (2002) Role of creatine and phosphocreatine in neuronal protection from anoxic and ischemic damage. Amino Acids 23; 221–229.
2. Blumberg, R. M., Cady, E., Wigglesworth, J. S., McKenzie, J. E. and Edwards, A. D. (1997) Relation between delayed impairment of cerebral energy metabolism and infarction following transient focal hypoxia-ischaemia in the developing brain. Exp. Brain Res. 113; 130–137.
3. Broughton, B., Reutens, D. C. and Sobey, C. G. (2009) Apoptotic mechanisms after cerebral ischemia. Stroke 40; e331.
4. Brustovetsky, N., Brustovetsky, T. and Dubinsky, J. M. (2010) On the mechanisms of neuroprotection by creatine and phosphocreatine. J. Neurochem. 76; 425–434.
5. Chambers, D. J., Haire, K., Morley, N., Fairbanks, L., Strumia, E., Young, C. P., et al. (1996) St. Thomas' Hospital cardioplegia: enhanced protection with exogenous creatine phosphate. Ann. Thorac. Surg. 61; 67–75.
6. Donnan, G. A., Fisher, M., Macleod, M. and Davis, S. M. (2008) Stroke. Lancet 371; 1612–1623.
7. Engelhard, K., Werner, C., Kaspar, S., Möllenberg, O., Blobner, M., Bachl, M., et al. (2002) Effect of the alpha2-agonist dexmedetomidine on cerebral neurotransmitter concentrations during cerebral ischemia in rats. Anesthesiology 96; 450–457.
8. Gonzalez, F. F. and Ferriero, D. M. (2009) Neuroroprotection in the Newborn Infant. Clin. Perinatol. 36; 859–880.
9. Imaizumi, Y., Mizushima, H., Matsumoto, H., Dohi, K., Matsumoto, K., Ohtaki, H., et al. (2001) Increased Expression of Interleukin-1b in Mouse Hippocampus after Global Cerebral Ischemia. Acta Histochem. Cytochem. 34; 357–362.
10. Jin, Y. J., Mima, T., Raicu, V., Park, K. C. and Shimizu, K. (2002) Combined argatroban and edaravone caused additive neuroprotection against 15 min of forebrain ischemia in gerbils. Neurosci. Res. 43; 75–79.
11. Jolkkonen, J., Puurnenen, K., Koistinaho, J., Kauppinen, R., Haapalinna, A., Nieminen, L., et al. (1999) Neuroprotection by the alpha2-adrenoceptor agonist, dexmedetomidine, in rat focal cerebral ischemia. Eur. J. Pharmacol. 372; 31–36.
12. Keller, J. N., Huang, F. F., Zhu, H., Yu, J., Ho, Y. S. and Kindy, T. S. (2000) Oxidative Stress-Associated Impairment of Proteasome Activity During Ischemia-Reperfusion Injury. J. Cereb. Blood Flow Metab. 20; 1467–1473.
13. Koizumi, J., Yoshida, Y. and Nakazawa, T. (1986) Experimental studies of ischemic brain edema. I. A new experimental model of cerebral embolism in rats in which recirculation can be introduced in the ischemic area. Nosotchu 8; 1–7.
14. Kuhmonen, J., Haapalimina, A. and Sivenius, J. (2001) Effects of dexmedetomidine after transient and permanent occlusion of the middle cerebral artery in the rat. J. Neural Transm. (Vienna) 108; 261–271.
15. Lee, J. J., Li, L., Jung, H. H. and Zuo, Z. (2008) Postconditioning with isoflurane reduced ischemia-induced brain injury in rats. Anesthesiology 108; 1055–1062.
16. Longa, E. Z., Weinstein, P. R., Carlson, S. and Cummins, R. (1989) Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke 20; 84–91.
17. Ma, D., Nishanthan, R. and Mervyn, M. (2004) alpha2-Adrenoceptor agonists: shedding light on neuroprotection? Br. Med. Bull. 71; 77–92.
18. Nakajima, T., Sato, K., Hanada, H., Watanabe, R., Harada, T., Choyke, P. L., et al. (2014) The effects of conjugate and light dose on photo-immunotherapy induced cytotoxicity. BMC Cancer 14; 389.
19. Nakano, T. and Okamoto, H. (2009) Dexmedetomidine-induced cerebral hyperperfusion exacerbates ischemic brain injury in rats. J. Anesthesia 23; 378–384.
20. Ohtaki, H., Dohi, K., Nakamachi, T., Yofu, S., Endo, S., Kudo, Y., et al. (2005) Evaluation of Brain Ischemia in Mice. Acta Histochem. Cytochem. 38; 99–106.
21. Prass, K., Royl, G., Lindauer, U., Freyer, D., Megow, D., Dirnagl, U., et al. (2006) Improved reperfusion and neuroprotection by creatine in a mouse model of stroke. J. Cereb. Blood Flow Metab. 27; 452–459.
22. Rajakumaraswamy, N., Ma, D., Hossain, M., Sanders, R. D., Franks, N. P. and Maze, M. (2006) Neuroprotective interaction produced by xenon and dexmedetomidine in vitro and in vivo neuronal injury models. Neurosci. Lett. 409; 128–133.
23. Schiffliti, D., Grasso, G., Conti, A. and Fodale, V. (2010) Anaesthetic-Related Neuroprotection Intravenous or Inhalational Agents? CNS Drugs 24; 893–907.
24. Selim, M. (2007) Perioperative stroke. N. Engl. J. Med. 356; 706–713.
25. Silva, M. N., Leite, J. S., Mello, M. F., Silva, K. V., Corzegno, K. B., de Souza, H. J., et al. (2016) Histologic evaluation of Ki-67 and cleaved caspase-3 expression in feline mammary carcinoma. J. Feline Med. Surg. 19; 440–445.
26. Sims, N. R. and Muyderman, H. (2010) Mitochondria, oxidative metabolism and cell death in stroke. Biochim. Biophys. Acta 1802; 80–91.
27. Stork, C. J. and Li, Y. V. (2009) Rising zinc: a significant cause of ischemic neuronal death in the CA1 region of rat hippocampus. J. Cereb. Blood Flow Metab. 29; 1399–1408.
28. Thornton, C., Rousset, C. I., Kichev, A., Miyakuni, Y., Vontell, R., Baburamani, A. A., et al. (2012) Molecular Mechanisms of Neonatal Brain Injury. Neurol. Res. Int. 2012; 506320.
29. Tong, L., Cai, M., Huang, Y., Zhang, H., Su, B., Li, Z., et al. (2014) Activation of K2P channel–TREK1 mediates the neuroprotection induced by sevoflurane preconditioning. Br. J. Anaesth. 113; 157–167.
30. Troy, C. M., Akpan, N. and Ying, Y. J. (2011) Regulation of Caspases in the Nervous System: Implications for Functions in Health and Disease. Prog. Mol. Biol. Transl. 99; 265–305.
31. Tüfek, A., Tokgöz, O., Aliosmanoglu, İ., Alabalik, U., Eviçyaoglou, O., Çiftçi, T., et al. (2013) The protective effects of dexmedetomidine on the liver and remote organs against hepatic ischemia reperfusion injury in rats. Int. J. Surg. 11; 96–100.
32. Tymianski, M. (2014) Stroke in 2013: disappointments and advances in acute stroke intervention. Nat. Rev. Neurool. 10; 66–68.
33. Vannucci, R. C. (1990) Current and potentially new management strategies for perinatal hypoxic-ischemic encephalopathy.
34. Wang, Z., Kou, D., Li, Z., He, Y., Yu, W. and Du, H. (2014) Effects of propofol-dexmedetomidine combination on ischemia reperfusion-induced cerebral injury. *NeuroRehabilitation* 10; 825–834.

35. Warner, S. F. S. (2007) Cerebral protection. *Br. J. Anaesth.* 99; 10–17.

36. Wass, C. T. and Lanier, W. L. (1996) Glucose modulation of ischemic brain injury: review and clinical recommendations. *Mayo Clin. Proc.* 71; 801–812.

37. Yagmurdur, H., Ozcan, N., Dokumaci, F., Kilinc, K., Yilmaz, F. and Basar, H. (2008) Dexmedetomidine reduces the ischemia-reperfusion injury markers during upper extremity surgery with tourniquet. *J. Hand Surg. Am.* 33; 941–947.

38. Yu, Y. Q., Liu, L. C., Wang, F. C., Liang, Y., Cha, D. Q., Zhang, J. J., *et al.* (2009) Induction profile of MANF/ARMET by cerebral ischemia and its implication for neuron protection. *J. Cereb. Blood Flow Metab.* 30; 79–91.

39. Zhu, Y. M., Wang, C. C., Chen, L., Qian, L. B., Ma, L. L., Yu, J., *et al.* (2013) Both PI3K/Akt and ERK1/2 pathways participate in the protection by dexmedetomidine against transient focal cerebral ischemia/reperfusion injury in rats. *Brain Res.* 1494; 1–8.